Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.51)
# 362
Out of 4,413 analysts
74
Total ratings
50.77%
Success rate
32.37%
Average return
Main Sectors:
35 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Reiterates: Overweight | $65 | $42.49 | +52.98% | 2 | Apr 10, 2024 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $60 | $21.96 | +173.22% | 8 | Apr 10, 2024 | |
| JANX Janux Therapeutics | Initiates: Overweight | $100 | $58.19 | +71.85% | 1 | Mar 20, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $60 → $70 | $27.03 | +158.97% | 5 | Mar 19, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $50 → $65 | $45.05 | +44.28% | 4 | Mar 4, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $35 → $40 | $25.72 | +55.52% | 3 | Mar 4, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $65 | $22.53 | +188.50% | 2 | Feb 27, 2024 | |
| CGON CG Oncology | Initiates: Overweight | $75 | $40.62 | +84.64% | 1 | Feb 20, 2024 | |
| RLYB Rallybio | Maintains: Outperform | $18 → $15 | $1.90 | +689.47% | 2 | Dec 21, 2023 | |
| KRYS Krystal Biotech | Maintains: Overweight | $160 → $180 | $159.67 | +12.73% | 3 | Dec 13, 2023 | |
| VTYX Ventyx Biosciences | Downgrades: In-Line | $43 → $5 | $4.68 | +6.84% | 2 | Nov 10, 2023 | |
| FDMT 4D Molecular Therapeutics | Initiates: Overweight | $32 | $25.39 | +26.03% | 1 | Oct 24, 2023 | |
| INSM Insmed | Maintains: Outperform | $32 → $42 | $25.59 | +64.13% | 2 | Sep 7, 2023 | |
| ERAS Erasca | Maintains: Outperform | $20 → $11 | $2.09 | +426.32% | 2 | Jun 6, 2023 | |
| RNA Avidity Biosciences | Upgrades: Outperform | $20 | $25.80 | -22.48% | 2 | May 22, 2023 | |
| BCEL Atreca | Downgrades: In-Line | $2 → $1.5 | $0.09 | +1,570.38% | 1 | Mar 30, 2023 | |
| NBIX Neurocrine Biosciences | Downgrades: In-Line | $140 → $130 | $143.03 | -9.11% | 1 | Nov 14, 2022 | |
| REGN Regeneron Pharmaceuticals | Downgrades: In-Line | $760 | $903.48 | -15.88% | 2 | Oct 17, 2022 | |
| SPRO Spero Therapeutics | Upgrades: Outperform | $2 → $8 | $1.55 | +417.80% | 3 | Sep 23, 2022 | |
| ZYME Zymeworks | Initiates: Outperform | $15 | $8.76 | +71.23% | 1 | Mar 15, 2022 | |
| VIRX Viracta Therapeutics | Initiates: Outperform | n/a | $0.82 | - | 1 | Mar 25, 2021 | |
| CGEM Cullinan Oncology | Initiates: Outperform | n/a | $28.10 | - | 1 | Feb 2, 2021 | |
| BYSI BeyondSpring | Initiates: Outperform | n/a | $2.06 | - | 1 | Dec 29, 2020 | |
| RGNX REGENXBIO | Upgrades: Outperform | n/a | $16.20 | - | 3 | Feb 25, 2019 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Outperform | n/a | $210.59 | - | 3 | Nov 16, 2018 | |
| BLUE bluebird bio | Upgrades: Outperform | n/a | $0.91 | - | 3 | Jun 19, 2018 | |
| INCY Incyte | Upgrades: Outperform | n/a | $52.94 | - | 2 | Jun 11, 2018 | |
| IONS Ionis Pharmaceuticals | Downgrades: In-Line | n/a | $43.01 | - | 2 | May 8, 2018 | |
| VYGR Voyager Therapeutics | Downgrades: In-Line | n/a | $8.36 | - | 2 | Mar 12, 2018 | |
| DNLI Denali Therapeutics | Downgrades: In-Line | n/a | $16.16 | - | 2 | Mar 12, 2018 | |
| QURE uniQure | Initiates: Outperform | n/a | $4.57 | - | 1 | Nov 7, 2017 | |
| BOLD Boundless Bio | Downgrades: In-Line | n/a | $10.00 | - | 2 | Oct 16, 2017 | |
| TBPH Theravance Biopharma | Initiates: Outperform | n/a | $8.84 | - | 1 | Aug 17, 2017 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | n/a | $83.33 | - | 1 | Aug 17, 2017 | |
| ABBV AbbVie | Initiates: Outperform | n/a | $161.72 | - | 1 | Aug 17, 2017 |
Xenon Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $65
Current: $42.49
Upside: +52.98%
Longboard Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $60
Current: $21.96
Upside: +173.22%
Janux Therapeutics
Mar 20, 2024
Initiates: Overweight
Price Target: $100
Current: $58.19
Upside: +71.85%
BridgeBio Pharma
Mar 19, 2024
Maintains: Overweight
Price Target: $60 → $70
Current: $27.03
Upside: +158.97%
Crinetics Pharmaceuticals
Mar 4, 2024
Maintains: Overweight
Price Target: $50 → $65
Current: $45.05
Upside: +44.28%
Mirum Pharmaceuticals
Mar 4, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $25.72
Upside: +55.52%
Rocket Pharmaceuticals
Feb 27, 2024
Maintains: Overweight
Price Target: $65
Current: $22.53
Upside: +188.50%
CG Oncology
Feb 20, 2024
Initiates: Overweight
Price Target: $75
Current: $40.62
Upside: +84.64%
Rallybio
Dec 21, 2023
Maintains: Outperform
Price Target: $18 → $15
Current: $1.90
Upside: +689.47%
Krystal Biotech
Dec 13, 2023
Maintains: Overweight
Price Target: $160 → $180
Current: $159.67
Upside: +12.73%
Ventyx Biosciences
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $4.68
Upside: +6.84%
4D Molecular Therapeutics
Oct 24, 2023
Initiates: Overweight
Price Target: $32
Current: $25.39
Upside: +26.03%
Insmed
Sep 7, 2023
Maintains: Outperform
Price Target: $32 → $42
Current: $25.59
Upside: +64.13%
Erasca
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.09
Upside: +426.32%
Avidity Biosciences
May 22, 2023
Upgrades: Outperform
Price Target: $20
Current: $25.80
Upside: -22.48%
Atreca
Mar 30, 2023
Downgrades: In-Line
Price Target: $2 → $1.5
Current: $0.09
Upside: +1,570.38%
Neurocrine Biosciences
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $143.03
Upside: -9.11%
Regeneron Pharmaceuticals
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $903.48
Upside: -15.88%
Spero Therapeutics
Sep 23, 2022
Upgrades: Outperform
Price Target: $2 → $8
Current: $1.55
Upside: +417.80%
Zymeworks
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $8.76
Upside: +71.23%
Viracta Therapeutics
Mar 25, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.82
Upside: -
Cullinan Oncology
Feb 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $28.10
Upside: -
BeyondSpring
Dec 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.06
Upside: -
REGENXBIO
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $16.20
Upside: -
Madrigal Pharmaceuticals
Nov 16, 2018
Upgrades: Outperform
Price Target: n/a
Current: $210.59
Upside: -
bluebird bio
Jun 19, 2018
Upgrades: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Incyte
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $52.94
Upside: -
Ionis Pharmaceuticals
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $43.01
Upside: -
Voyager Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $8.36
Upside: -
Denali Therapeutics
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $16.16
Upside: -
uniQure
Nov 7, 2017
Initiates: Outperform
Price Target: n/a
Current: $4.57
Upside: -
Boundless Bio
Oct 16, 2017
Downgrades: In-Line
Price Target: n/a
Current: $10.00
Upside: -
Theravance Biopharma
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $8.84
Upside: -
BioMarin Pharmaceutical
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $83.33
Upside: -
AbbVie
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $161.72
Upside: -